Drug Accountability. Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital
|
|
- Lee Blankenship
- 5 years ago
- Views:
Transcription
1 Drug Accountability Kevin E. Anger PharmD, BCPS Manager Investigational Drug Services Brigham and Women s Hospital
2 Session Objectives Define drug accountability and drugs in need of these accountability processes Discuss best practices, regulatory requirements surrounding drug accountability Describe key drug accountability processes
3 Disclosures The author of this presentation has no disclosures concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation
4 Session Outline Define investigational drugs and drugs in need of drug accountability records Best practice and regulatory requirements International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice CMS/ The Joint Commission AAHRPP FDA requirements/expectations Investigator, sponsors FDA approach Drug accountability processes Investigational Drug Service or Research Pharmacy Logs and Records
5 Drug Accountability Defined Drug accountability is the process of documenting all aspects of drug receipt, storage, use, and disposition so that a full accounting of each unit can be made.
6 Poll the Audience: Which of the following types of drugs is subject to research drug accountability? Investigational drugs Investigational new drugs Investigational Products Commercially available drugs
7 Investigational Drug Nomenclature Study Drug: Any drug used in a research study Trade or commercial drug: is FDA approved for use in the United States Investigational New Drug: A drug or biological product that is used in a clinical trial but has not been approved by the Food and Drug Administration (FDA) (the drug is either not available for a doctor to prescribe or is available but has not been approved by FDA for the use being studied). Investigational drug: a trade and/or investigational new drug being used in a research protocol. Investigational Product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. ICH E6 GCP; 1.33
8 Poll the Audience: Which group drives the regulations of drug research and accountability? FDA Partners IRB Massachusetts DPH Research sponsors
9 What rules do I have to play by Federal with Investigational Drugs? FDA DEA State DPH/board of pharmacy Heath System/Hospital IRB Institutional Policies and Procedures CMS/Joint Commission Sponsor Drug accountability = Rules/regs + resources = Call IDS pharmacy
10 Key AAHRPP Accreditation Organization (Standard I-7): Standards The Organization has and follows written policies and procedures to ensure that the use of any investigational or unlicensed test article complies with all applicable legal and regulatory requirements. IRB (Standard II-3): The IRB or EC approves each research protocol or plan according to criteria based on applicable laws, regulations, codes, and guidance. Researcher Standard III-2: Researchers and Research Staff meet requirements for conducting research with participants and comply with all applicable laws, regulations, codes, and guidance; the Organization s policies and procedures for protecting research participants; and the IRB s or EC s determinations. AAHRPP = Association for the Accreditation of Human Research Protection Programs
11 Investigational Drugs in the eyes of The Joint Commission The JC considers all investigational drugs to be high risk medications = pharmacy controls MM The hospital safely manages investigational medications Hospital s written process specifies that the pharmacy controls the storage, dispensing, labeling, and distribution of investigational medications.
12 Best Practice on human research trials International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good clinical practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve the participation of human subjects. ICH E6 GCP;
13 ICH/FDA GCP: Investigator Responsibilities Responsibility for investigational product(s) accountability at the trial site(s) rests with the investigator/institution Where allowed/required, the investigator/institution may/should assign some or all of the investigator's/institution s duties for investigational product(s) accountability at the trial site(s) to an appropriate pharmacist or another appropriate individual who is under the supervision of the investigator/institution. ICH E6 GCP; 4.6
14 ICH/FDA GCP: Investigator Responsibilities The investigator/institution and/or a pharmacist who is designated by the investigator/institution, should maintain records of product delivery, inventory onsite, use by subject and return or disposition of unused products. Records should include dates, quantities, batch/serial numbers, expiration dates, and the unique code numbers assigned to the investigational product(s) and trial subjects. Investigators should maintain records reconcile all investigational product(s) received from the sponsor. ICH E6 GCP; 4.6
15 ICH/FDA GCP: Investigator Responsibilities Instructions for drug accountability Shipping records for at least an initial receipt of IP(s) and subsequent shipments. Ongoing accountability records and final records after study closure ICH E6 GCP; 8
16 FDA inspector expectations/targets Physical drug storage and labeling Documentation Accountability logs Patient cards or dispensing records Drug integrity testing (COA, temperature) Disposition records (destruction, transfer) Conduct a reconciliation process based upon available records
17 What we never want to see Dear Dr : During the period to, Investigators from the Food and Drug Adminstration (FDA), inspected your conduct of clinical studies under IND At the end of the inspection, a Form FDA 483 was issued to you. We determined that you violated regulations governing the proper conduct of clinical studies involving investigational new drugs; as published in Title 21; Code of Federal Regulations (CFR). The applicable provisions of the CFR are cited for each violation.
18 You failed to. Form 483 Provide adequeate source documents Maintain product accountability records for the quantity of the test article and the date of receipt. Provide or maintain complete/accurate accountability records on dispensing or distribution Account for missing study drug Document the destruction of the contaminated vials
19 IDS Pharmacy and Drug Accountability The PI delegates the entirely or components of drug accountability to the IDS Pharmacist IDS Pharmacy is involved in: Inventory management and security Dispensing (labeling) Temperature monitoring Chain of custody Disposition or destruction
20 What is the pharmacist doing to maintain drug accountability Record availability (Paper and electronic) Investigational Brochure Most recent approved protocol Policies and Procedures Drug Package Slip (record of receipt: date received, who received drug, amount) Pharmacy inventory tracking system (database, log) Copy of Investigational Drug Label Patient card/subject card or dispense reports Electronic documentation: EPIC and IDS-IS (BWH)
21 Inventory Management: Drug Receipt Documentation Documentation by the authorized IDS pharamcist: Quantity of study product received Reference numbers Acceptability of condition of shipment Date IP received Signature of IDS staff member Combination of paper based and electronic methods
22 Drug Dispensation Documentation by the authorized IDS pharamcist using paper and electronic resources Authorized prescriber Patient information Dose, dilution Lot/batch/kit# Expiration dates Preparation documentation Ex. Thaw times for frozen products 21 CFR (a) and (a)].
23 Chain of Custody Documentation Drug administation documentation (when applicable) Physcian, Nurse, PA, pharmacist Administration route, time Drug Dispostion Pharmacist returns product to the IND holder/ sponsor Destroys if instructed by the IND holder/sponsor
24 What Resources are used for Drug Accountability? Internal and external drug accountability logs Types of log used Electronic logs and reports (internal and external programs) Paper logs (PDF, excel, word) Sponsors often want their study specific form used for accountability Double documentation is common to meet sponsor and institutional accountability standards
25 Pearls of the Accountability Log Real time logging Patient or subject card may be helpful adjunct Flagging blinded studies Use of (+) or (-) for inventory changes Crossing out of unused lines depending upon paper based log structure Crossouts, adjustments, red ink, and white out of drug quantities are auditor red flags!
26 NIH toolkit example IP Accountability log Investigational Product Accountability Log: Stock Record Name of Institution: Investigator Name: Protocol No.: Protocol Title: Product Name: Manufacturer: Dose Form and Strength: Dispensing Area: Line No. 1. Date Dispensed To / Received From Dose Quantity Dispensed and/or Received Ex. 15Feb2012 Manufacturer 10 mg tabs Balance Forward / Balance Lot No. Recorder s Initials JAD
27 National Cancer Institute Drug Accountability Log
28 Example Sponsor Provided Drug Accountability Log
29 Example Electronic log Report from BWH IDS-IS
30 How can the investigator help IDS with drug accountability? Communication, communication, communication Drug shipments notifications Working with sponsors Ensuring the IDS has the resources needed to support accountability needs Reaching out to our service upstream of the grant and IRB process
31 Key Takeaways on Drug Accountability With good drug accountability, at any stage, the investigator, pharmacist, and the sponsor should know where the investigational products are located Drug accountablity is a key target of the many agencies involved in overseeing investigaitional drug research studies Working with your research pharmacist is key to ensuring drug accountability documentation is in audit proof
32 References and Recommended Readings Guidance for industry. E6 good clinical practice, consolidated guidance. Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Control : Center for Biologics Evaluation and Research. pdf ASHP guidelines on clinical drug research. American Society of Health-System Pharmacists. Am J Health Syst Pharm Feb 15;55(4): FDA investigations operations manual (IOM) Medication Management Overview (Hospital). Standard MM The Joint Commission E-edition. Jan 1, 2012 AAHRPP Accreditation Standards. NIH toolkit for clinical researchers
I. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationPREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS CME Disclosure Statement The North Shore LIJ Health System adheres
More informationTITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationINVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN
Policy/ Procedure # INVESTIGATIONAL PRODUCT ACCOUNTABILITY, STORAGE, DISPENSING, TRANSPORT AND RETURN 21 Effective Date June 2018 Category Global Last Review/Revision March 2017 Sub-Category Research Standards
More informationEuropean Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)
European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand
More informationPOLICY Investigational Drug Service Transport
Investigational Drug Service Huntsman Cancer Hospital 1950 Circle of Hope, Suite 2110 Salt Lake City, Utah 84112 POLICY Investigational Drug Service Transport Purpose A. This policy establishes procedures
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationStandard Operating Procedures
Standard Operating Procedures 5.14.1 Investigational Product Handling and Storage History Version Date Author Reason 1.1 23 rd August B Fazekas New procedure 2007 1.2 16 th October 2007 B Fazekas Update
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationThe Right Prescription for Working with Investigational Drug Service at BMC
The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationThe purpose of these guidelines is to describe a standardized approach for the management of
ASHP Guidelines for the Management of Investigational Drug Products Purpose The purpose of these guidelines is to describe a standardized approach for the management of investigational drug products by
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty
More informationDocument Number: SOP IV Original SOP: March 2010 Revision Number: mjb SOP IV: Transport to Satellite Pharmacies Effective Date: April 2013
S.O.P. IV TRANSPORT of Study Medications to Satellite Pharmacies I. PURPOSE A. To clarify the responsibilities and procedures of the Investigational Pharmacy in the transportation of study medications
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationGuidance on Requirements of the Sponsor and the Investigator as a Sponsor
Guidance on Requirements of the Sponsor and the Investigator as a Sponsor University of Colorado Denver (UCD) secures assurances from the sponsor or the investigator-sponsor* that the manufacture and formulation
More information10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP
PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Presented by Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationPatricia Novo, MPA, MPH Beth Jeffries, BS, CCRP
PREPARATION FOR DRUG MANAGEMENT AND ACCOUNTABILITY IN A CTN CLINICAL TRIAL Presented by Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationProcedures at DF/HCC Transferring Site
POLICY #: INV-101 Page: 1 of 5 1. POLICY STATEMENT: The transfer of investigational drug from main DF/HCC delivery site to another location is permissible and may require authorization from the Sponsor.
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies
ECTU Central Office SOP ECTU_TM_17 Management of Trial (IMP) Supplies SOP number: ECTU TM 17 Signature Date Authored by: Holly Ennis, Trial Manager 6 th Sept 2017 Reviewed by: Laura Forsyth, Trial Manager
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter only apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationInvestigator s Handbook
Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationThe following scenario illustrates the supply, receipting and movement of ANODE packs. Allocation and shipment of IMP
Guidance Sheet 11 IMP Management and Stock Control Participants in the ANODE Trial will receive an intravenous (IV) dose of either co-amoxiclav or an unmatched inactive placebo (0.9% saline). This is an
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationPHARMACY, MEDICINES & POISONS BOARD
PHARMACY, MEDICINES & POISONS BOARD PHARMACY GUIDELINES FOR INVESTIGATIONAL DRUGS A. Purpose These guidelines are principally derived and adapted from guidelines from various sources within the SADC region.
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationSTUDY REQUEST FORM AND TRAQ DSS FORM
Research Road Map April 2017 In This Issue Pharmacy Services for Research Study Request Form and TRAQ DSS FORM Management of Investigational Drugs Pharmacy Standard Operating Procedures IDS Team Qualifications
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationDana-Farber/Harvard Cancer Center Site Management Plan
Dana-Farber/Harvard Cancer Center Site Management Plan 1.0 Oversight Responsibilities of the Overall Principal Investigator and Site Responsible Investigator A system using an Overall Principal Investigator
More informationINVESTIGATIONAL DRUG SERVICE (IDS) Standard Operating Procedures
INVESTIGATIONAL DRUG SERVICE (IDS) Standard Operating Procedures The Investigational Drug Service (IDS) strives to meet or exceed the standards of Good Clinical Practice (GCP). 1. UC Davis Health (UCDH)
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationTitle: Department: Approved by: Director, Human Research Review and Compliance
Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationSOP NUMBER: SC-404 Page 1 of 3
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Last Revised: 1/2016 Prior Version: None Title: Transporting Investigational Product to Other Sites SOP NUMBER: SC-404 Page 1 of 3 1. PURPOSE: UHCMC
More informationAuthor Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document
SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 02/12/2019 and available online at https://federalregister.gov/d/2019-01962, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationPreparing for Close-Out of Studies and Sites
Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationIND Drug Log Guidelines
9/24/2009 IND Drug Log Guidelines 1) An NCI DARF (Drug Accountability Record Form) should be kept on each strength of investigational drug. An investigational drug is considered to be any drug (including
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationInvestigational Product (Pharmaceutical) Management. Sudhakar Bangera MD, MMedSc Program Director, CDSA
Investigational Product (Pharmaceutical) Management Sudhakar Bangera MD, MMedSc Program Director, CDSA Investigational Product Definition (CDSCO GCP) - A pharmaceutical product (including the Comparator
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationPresented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationNational Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services
National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute
More informationBRIEFING 1168 Compounding for Phase I Investigational Studies,
BRIEFING 1168 Compounding for Phase I Investigational Studies, PF 39(5) [Sept. Oct. 2013]. The current proposed chapter in PF 43(3) [May June 2017] is posted online at www.usp.org/usp-nf/notices/compounding-forphase-i-investigational-studies
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationSPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT
SPONSOR INVESTIGATIONAL MEDICINAL PRODUCT (IMP) MANAGEMENT DOCUMENT NO.: GS010 v1.0 AUTHOR: Vikki Young ISSUE DATE: 28 MAY 2018 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research &
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More informationSELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
More informationRole of Academic Investigators in Drug Development
DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator
More informationGuidance for Industry
Guidance for Industry Handling and Retention of BA and BE Testing Samples U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 2004
More informationHOPA INVESTIGATIONAL DRUG SERVICE BEST PRACTICE STANDARDS
HOPA INVESTIGATIONAL DRUG SERVICE BEST PRACTICE STANDARDS 8735 W. Higgins Road, Suite 300 Chicago, IL 60631-2738 877.467.2791 info@hoparx.org www.hoparx.org Copyright 2014 Hematology/Oncology Pharmacy
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationPOINT Clinical Research Collaboration SOP-DH-CA.01 v2.0 POINT Trial Canadian Clinical Sites: Study Drug Handling Effective Date: 08/30/2013
TABLE OF CONTENTS 1. INTRODUCTION... 3 2. PURPOSE... 3 3. SCOPE... 3 4. RESPONSIBLE PERSONNEL AND CONTACT INFORMATION... 3 5. DEFINITIONS/ABBREVIATIONS AND RESOURCES... 5 6. PROCESS DETAIL DESCRIPTION...
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationDate: 2 nd June 2010 Version: 3 Page 1 of 16 AND LABELLING (NWORTH 3.08) Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10
Page 1 of 16 STANDARD OPERATING PROCEDURE FOR TRIAL SUPPLIES AND LABELLING (NWORTH 3.08) Approvals Principal Author Name: E. Bedson Signature: E. Bedson Date:15/06/10 Quality Assurance Officer Name: D.
More informationKingston Health Sciences Centre Pharmacy Services Investigational Drug Service (IDS) COST ESTIMATE REQUEST FORM Version July 2017
Please complete the KHSC Pharmacy Services Study Request Form and ATTACH the Form to your TRAQ DSS FORM prior to submission. If you forgot to attach the Form to your TRAQ DSS FORM prior to submission,
More informationKingston Health Sciences Centre Pharmacy Services Investigational Drug Service (IDS) COST ESTIMATE REQUEST FORM Version June 2018
Please complete the KHSC Pharmacy Services Study Request Form and ATTACH the Form to your TRAQ DSS FORM prior to submission. If you forgot to attach the Form to your TRAQ DSS FORM prior to submission,
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationClinical Research & ICH GCP E6(R2) (Basic / Refresher Training):
Clinical Research & ICH GCP E6(R2) (Basic / Refresher Training): Principles of GCP, Investigator Responsibilities, Essential Documents v3 01-Feb-2017 Objectives To provide refresher training on ICH GCP
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationIBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol
IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol Use this checklist to assemble your request for your institution s IBC to review a specific protocol. If WIRB does not already administer
More information